Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Lymphoid 1

Conditions

Lymphoma, Non-Hodgkin 15Neoplasm Metastasis 9Lymphoma, Large B-Cell, Diffuse 8Breast Neoplasms 8Neoplasms 6Lymphoma, Follicular 6Lymphoma 5Multiple Myeloma 4Lymphoma, B-Cell, Marginal Zone 4Leukemia, Lymphocytic, Chronic, B-Cell 4Endometrial Neoplasms 4Recurrence 3Prostatic Neoplasms 3Ovarian Neoplasms 3Lymphoma, Mantle-Cell 3Hodgkin Disease 3Urinary Bladder Neoplasms 2Thyroid Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Pancreatic Neoplasms 2Lymphoma, T-Cell, Peripheral 2Hematologic Neoplasms 2Colonic Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Carcinoma, Hepatocellular 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Ureteral Neoplasms 1Triple Negative Breast Neoplasms 1

Interventions

Rituximab 112Cyclophosphamide 103fludarabine 61Doxorubicin 33Vincristine 31Etoposide 31Prednisone 30Lenalidomide 24ibrutinib 22fludarabine phosphate 21Immunotherapy, Adoptive 19Bendamustine Hydrochloride 19obinutuzumab 18Cytarabine 18pembrolizumab 16Magnetic Resonance Spectroscopy 16Bortezomib 14Specimen Handling 13Dexamethasone 13polatuzumab vedotin 12CT-P10 12venetoclax 11pirtobrutinib 11Gemcitabine 11Carboplatin 11glofitamab 10zanubrutinib 9Nivolumab 9Mycophenolic Acid 9Melphalan 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, B-Cell × copanlisib × Clear all
NCT03886649 2022-04-01

Copanlisib in Combination With Venetoclax in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma.

Swiss Cancer Institute

Phase 1 Terminated
7 enrolled
LymphoidSarcoma

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Dendritic Cell Sarcoma, Interdigitating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡